Ugly results for Ugg – plus Teva and Sanuk Q3 sales

We listened to Deckers call today. Details about the many challenges for Ugg in Q3, plus details about how Sanuk and Teva performed, why Deckers cut its forecast, much more.
Published: May 13, 2013

 

THIS ARTICLE IS AVAILABLE TO OUR EXECUTIVE EDITION MEMBERS.

If you think you are already an Executive Edition member and you’re getting this message, it’s possible your membership is on hold because your credit card expired. You can update your card here. If you have any trouble and need help, please click here to email our customer care specialist.

Strategy & Planning Series
Strategy & Planning Series
Strategy & Planning Series
Strategy & Planning Series